Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma

Xinjing Ding  
First Affiliated Hospital of Nanchang University

Jianghua Ding (✉️ doctor0922@126.com)  
Jiujiang Medical College: Jiujiang University Medical College  
https://orcid.org/0000-0003-4476-4398

Hong Gu  
Jiujiang University

Chuanxiang Zhong  
Jiujiang University Medical College

Research Article

Keywords: Long-acting G-CSF, primary prophylaxis, early infection, newly diagnosed multiple myeloma

DOI: https://doi.org/10.21203/rs.3.rs-741561/v1

License: ☇️ 📧 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose

This study sought to compare the efficacy of prophylactic long-acting and standard granulocyte colony-stimulating factor (G-CSF) on febrile neutropenia, early infections, and treatment delay in patients with newly diagnosed multiple myeloma receiving the therapeutic regimen of bortezomib, lenalidomide, and dexamethasone (BLD).

Methods

A prospective study with 68 consecutive patients with multiple myeloma was conducted in three regional hospitals. Participants were randomly treated with the BLD regimen in combination with prophylactic long-acting G-CSF (treatment group) or standard G-CSF (control group). The primary endpoints were the incidence rates of febrile neutropenia, early infection, and treatment delays. The secondary endpoint was clinical outcomes.

Results

Thirty-three patients were assigned to the treatment group and thirty-five patients were assigned to the control group. The incidence of febrile neutropenia was 6.1% and 17.1% in the treatment and control groups, respectively ($p = 0.297$). However, the rates of early infection and treatment delay were markedly lower in the treatment group than in the control group (6.1% vs. 25.7% and 9.1% vs. 31.4%; $p < 0.05$). Notably, all early infections occurred during the first four cycles of BLD therapy, and the most common type of infection was pneumonia. No significant difference in clinical efficacy was found between the two groups. All participants achieved at least partial remission.

Conclusions

Prophylactic administration of domestic long-acting G-CSF markedly reduced the rates of early infection and treatment delay as compared with standard G-CSF in patients newly diagnosed with multiple myeloma. Notably, all early infections occurred during the first four cycles of BLD therapy. As such, it seems appropriate to administer long-acting G-CSF with the aim of primary prophylaxis of early infection, particularly within the first four courses of chemotherapy in the setting of newly diagnosed multiple myeloma.

1. Introduction

Patients with multiple myeloma (MM) experience an increased chance of infection than the general population, with the risk being 13 times more than that for pneumonia and 30 times more than that for
The greater risk of infection in patients with MM can be attributed to advanced age; disease-related immunodeficiency involving humoral immunity and treatment-related toxicity, particularly for myelotoxicity; and comorbidities such as diabetes and chronic obstructive pulmonary diseases. Notably, the infection itself also contributes to the progression of MM via the production of interleukin-6 and the activation of Toll-like receptors on myeloma cells [3]. Importantly, infection is the leading cause of morbidity and mortality among patients with MM, with around 45% of deaths in this population resulting from infection [2]. Currently, with the continual advent of several novel anti-myeloma drugs, the five-year survival rate of patients with MM has risen to about 60% [4]. Therefore, it is of paramount importance to continue efforts to prevent deaths from infection among these individuals.

The entry of infectious organisms, including bacteria and viruses, into the body can occur during any treatment phase in patients with MM. The result of the FIRST study, which examined the prevalence of infections among patients with MM, showed that the infection rate was 56.2% over the initial four cycles of the treatment period. In particular, 30% of infections occurred in the first month of treatment [5]. So, more attention should be paid to the prevention of infection during the first and second courses of treatment in patients with MM. As is well known, the most common therapy for bacterial infections is the use of antibiotics. However, European Organization for Research and Treatment of Cancer (EORTC) guideline does not recommend universal antibacterial prophylaxis in patients with hematological and solid tumors, including those with MM [6, 7].

In patients with MM, neutropenia not only causes treatment delays or dose reductions but is also seen as an independent risk factor for a poor prognosis [3]. The national cancer center network (NCCN) guideline on managing febrile neutropenia (FN) recommends prophylactic treatment of granulocyte colony-stimulating factor (G-CSF) for patients receiving chemotherapy and at high risk of more than 20% of developing FN. For patients newly diagnosed with MM, up to 56.2% experienced infections during their initial four courses of chemotherapy [5]. Importantly, there is a direct correlation between a lower neutrophil cell count and a greater risk of infection (mainly bacterial and fungal infections) in patients with MM [8]. Therefore, it is reasonable to adopt prophylactic use of G-CSF for infection in patients with MM with neutropenia.

In recent years, long-acting G-CSF therapies, such as pegfilgrastim and biosimilar drugs, have been widely applied in cancer-related supportive care due to their higher efficacy and better adherence. The vast majority of clinical studies have focused on the mobilization outcome of pegfilgrastim in autologous stem cell transplantation of MM [9]. In contrast, only a few studies (including just three clinical trials and three observational studies) have considered primary prophylaxis with pegfilgrastim for FN in refractory and relapsed patients with MM who received lenalidomide- or bendamustine-based regimens [10–15]. These studies reported the supportive role of pegfilgrastim in ensuring scheduled chemotherapy and decreasing the rates of neutropenia and infection; however, all investigations were both single-armed or retrospective studies and merely focused on patients with recurrent or refractory MM. As mentioned above, the risk of infection is highest during the first four months of treatment, thanks to the huge tumor burden and frail physical status typically present in patients with MM [5]. In the present study, we
included patients newly diagnosed with MM, aiming to compare the primary prophylactic efficacy of early infection using long-acting and standard G-CSF. The primary endpoints were the incidence rates of early infection and treatment delays in patients newly diagnosed with MM.

2. Methods

2.1. Patients

A total of 68 consecutive patients with MM were included from March 1, 2019 to July 20, 2021, at three regional hospitals. The eligibility criteria for inclusion in this study were as follows: (1) newly diagnosed with systemic MM; (2) aged 18–75 years; (3) Eastern Cooperative Oncology Group (ECOG) score of less than three points; and (4) no history of cardiac arrhythmias, congestive heart failure, or severe coronary artery disease.

All patients received anti-myeloma therapy, except autologous hematopoietic stem cell transplantation. The last study follow-up date was June 30, 2021. Patients with amyloidosis or without a willingness to receive treatment were excluded.

2.2. Treatment protocol

According to medication use of long-acting or standard G-CSF, all patients were randomly divided into two groups of 33 patients treated with the chemotherapy with long-acting G-CSF (treatment group) and 35 patients treated with the chemotherapy with standard G-CSF (control group).

The specific chemotherapy protocol, known as the BLD regimen, was as follows: 1.3 mg/sqm of bortezomib (Qilu-pharma, Jinan, China) on days 1, 4, 8, and 11; 20–25 mg/d of lenalidomide (SL Pharm, Beijing, China) for 14 days; and 20 mg/d of dexamethasone on days 1, 2, 4, 5, 8, 9, 11, and 12. According to the regimens described in the literature by Cerchione et al. [13], the patients in the treatment group were given long-acting G-CSF (6 mg) (Qilu-pharma, Jinan, China) subcutaneously with a single administration performed on the sixth day as primary prophylaxis, while the patients in the control group were treated by primary prophylaxis of standard G-CSF (5 µg/kg/day on days 6–8 of each cycle) (Qilu-pharma, Jinan, China). For the purposes of this study, a treatment cycle was 28 days in length, and all patients underwent 6–8 courses of chemotherapy and then continued to receive lenalidomide therapy until an unacceptable adverse event or disease progression occurred.

Blood routine, liver and kidney functions, C-reactive protein level, immunoglobulin concentration, and serum-free light chain results were examined before and after chemotherapy of each cycle.

2.3. Study endpoints

The primary endpoints were the incidence rates of FN, early infection, and treatment delay. An episode of FN was defined as follows: (1) fever, a single axillary temperature greater than 38.0°C or an axillary temperature greater than 37.5°C lasting 1 h and (2) neutropenia, defined according to the FN guidelines
from NCCN [16]. The criteria for infection in this study were defined as an increased body temperature of above 37.5°C or the isolation of a microbial agent in patients with concomitant clinical symptoms (such as pneumonia) and/or an increased C-reactive protein level above the normal value [17]. Early infection was deemed as that occurring during the first four months of treatment [5]. Treatment delay referred to chemotherapy administration occurring more than two days after the scheduled date. The secondary endpoint was patient clinical outcomes.

Efficacy was assessed every two cycles of treatment according to the new categories from the International Myeloma Working Group, which include stringent complete remission (sCR), complete remission (CR), very good partial remission (VGPR), partial remission (PR), minimal response (MR), stable disease, and progressive disease [18].

2.4. Statistical analysis

All statistical analyses were conducted using the Statistical Package for the Social Sciences software program (version 26; IBM Corporation, Armonk, NY, USA). An independent $t$-test was run to examine the differences between the two groups. Fisher’s exact test and a chi-squared test were employed to compare the binary outcomes. The degree of clinical efficacy was analyzed by Ridit analysis. A $p$-value less than 0.05 was considered to be statistically significant, based on a two-sided test.

3. Results

3.1 Clinical characteristics

A total of 68 patients with MM were enrolled in this study, including 33 and 35 patients assigned to the treatment and control groups, respectively. As shown in Table 1, the two groups were very similar in terms of baseline characteristics, including age, sex, Revised International Staging System (R-ISS) stage, ECOG score, and cytogenetic abnormalities ($p > 0.05$).
Table 1
Comparison of clinical characteristics between the treatment and control groups

| Characteristic         | Treatment group, n (%) | Control group, n (%) | p-value |
|------------------------|------------------------|----------------------|---------|
| Number                 | 33                     | 35                   | -       |
| Age, years Median (range) | 62 (54–71)            | 65 (56–75)           | 0.3538  |
| Sex                    |                        |                      |         |
| Male                   | 18 (54.6%)             | 16 (45.7%)           | 0.4666  |
| Female                 | 15 (45.4%)             | 19 (54.3%)           |         |
| R-ISS stage            |                        |                      |         |
| I–II                   | 16 (48.5%)             | 15 (42.8%)           | 0.9253  |
| III                    | 17 (51.5%)             | 20 (57.1%)           |         |
| ECOG                   |                        |                      |         |
| 0–1                    | 28 (84.8%)             | 27 (77.1%)           | 0.4193  |
| ≥ 2                    | 5 (15.2%)              | 8 (22.9%)            |         |
| Cytogenetic abnormality|                        |                      |         |
| Standard risk          | 13 (39.4%)             | 18 (51.4%)           | 0.3193  |
| High risk              | 20 (60.6%)             | 17 (48.6%)           |         |

3.2 Incidence rates of FN, early infection, and treatment delay

Throughout the period of chemotherapy, 6.1% and 17.1% of cases of FN were detected in the treatment and control groups, respectively, but there was no statistical difference between the two groups. However, as shown in Table 2, we discovered that the rates of early infection and treatment delay in the treatment group were markedly lower than those in the control group. As shown in Table 3, all early infections occurred during the initial second to fourth cycles.
### Table 2
Clinical events between the treatment and control groups

| Event                  | Treatment group (n = 33), n (%) | Control group (n = 35), n (%) | p-value |
|------------------------|---------------------------------|------------------------------|---------|
| Febrile neutropenia    | 2 (6.1%)                        | 6 (17.1%)                    | 0.297   |
| Early infection        | 2 (6.1%)                        | 9 (25.7%)                    | 0.0278# |
| Treatment delay        | 3 (9.1%)                        | 11 (31.4%)                   | 0.0228# |

# The differences were statistically significant.

### Table 3
Comparison of early infections in patients between the treatment and control groups

| Type of infection               | Treatment group (n = 33), n | Control group (n = 35), n | Cycle sequence(s) of infection occurrence |
|---------------------------------|----------------------------|--------------------------|-------------------------------------------|
| Pneumonia                       | 1                          | 5                        | 2–4                                      |
| Colitis                         | 0                          | 2                        | 2–3                                      |
| Fever of unknown origin         | 1                          | 2                        | 2–4                                      |
| Total                           | 2                          | 9                        |                                           |

### 3.3 Clinical outcomes

All 68 patients completed at least six cycles of chemotherapy, and 60 (88.2%) patients completed the prescribed eight cycles. As shown in Table 4, there were marked differences in clinical outcomes between the two groups. No stringent complete remission efficacy was found in either group; however, all patients achieved at least PR of their disease.
Table 4
Clinical outcomes between the treatment and control groups

| Efficacy | Treatment group (n = 33), n (%) | Control group (n = 35), n (%) | p-value |
|----------|--------------------------------|-------------------------------|---------|
| sCR      | 0 (0.0%)                       | 0 (0.0%)                      | 0.2305  |
| CR       | 3 (9.1%)                       | 1 (2.9%)                      |         |
| VGPR     | 23 (69.7%)                     | 22 (62.9%)                    |         |
| PR       | 7 (21.2%)                      | 12 (34.3%)                    |         |
| MR       | 0 (0.0%)                       | 0 (0.0%)                      |         |

4. Discussion

In the era of emerging novel treatments, the clinical outcomes of patients with MM have improved greatly to a five-year survival rate of 60% [4]. However, MM remains notorious for placing patients at high risk of infection, thanks to the impairment of host defenses, and ensuring treatment-related immunosuppression. Importantly, the risk of infection is the highest within the first four months after the initial diagnosis. Furthermore, infection contributes to approximately 45% of early deaths [2]. Although the transition from chemotherapy to novel agents has caused a marked decrease in the incidence of severe pneumonia, heightened rates of early infection and pneumonia persist. Nearly all recent studies investigating MM-related infection focused on patients with refractory and relapsed MM [10–15]. As compared with these patients, those newly diagnosed with MM also experience the same risk of infection [19]. Therefore, it is imperative to prevent the occurrence of infection in all patients with MM, particularly early infection within the first four months after diagnosis.

As the vast majority of infections are bacterial in nature, it is reasonable, logically, to administer antibiotics for the prevention of infection in patients with MM. A phase III study explored the effects of oral antibiotic prophylaxis, i.e., ciprofloxacin or trimethoprim-sulfamethoxazole, for the first two months on the incidence of infection in patients with newly diagnosed MM; however, this study showed that routine use of prophylactic antibiotics did not reduce the incidence of infection among patients with MM receiving induction chemotherapy [7]. Another retrospective study investigated the effect of levofloxacin prophylaxis for the prevention of severe infections in patients with MM being treated using bortezomib-based regimens and supports the prophylactic use of levofloxacin in MM cases due to the marked decrease in severe infection observed relative to the control group (30.9% vs. 17.5%; p = 0.037) [20]. A prospective phase III study (TEAMM) also revealed that prophylactic administration of levofloxacin during the first 12 weeks of anti-myeloma therapy significantly reduced the number of febrile episodes and deaths as compared with the control group (27% vs. 19%; p = 0.0018) [21]. Despite such positive results, the use of antibacterial prophylaxis for infection remains to be viewed with caution due to the limitation of about 50% of patients withdrawing from the TEAMM study [21]. Moreover, prophylactic
antibiotics can also increase the risk of *Clostridioides difficile* infection and antibiotic resistance. The discrepancy highlighted above was largely attributed to the significant differences in therapeutic regimens and enrolled patients with MM. Hence, available data on prophylactic antibiotics for early infection remain inconsistent and should not be considered to indicate the best course of action in patients with MM [19]. Currently, prophylactic antibiotics for early infection should be limited to use in high-risk patients who have the heightened potential to experience severe-grade and prolonged neutropenia during anti-myeloma treatment [22].

In the clinical setting, neutropenia has been strongly associated with the incidence of infection in patients with MM [23, 8]. Owing to the fragile performance status and multiple comorbidities (e.g., diabetes) of patients with MM, neutropenia-related infection may be a potentially life-threatening condition in such patients, which also results in treatment delay and the final outcome. Thus, the idea of G-CSF as a feasible treatment option has emerged to prevent neutropenia-related infections in those with MM. As noted previously, long-acting G-CSF has been documented for prophylaxis of infection mainly in refractory and relapsed patients with MM [10–15]. Enlighted by such previous findings, we investigated the effect of long-acting G-CSF on preventing infection among those with newly diagnosed MM.

In our study, the incidence rates of early infection and treatment delay were markedly lower in the long-acting G-CSF group than in the standard G-CSF group. The underlying mechanisms were attributed to the longer circulation half-life and lower immunogenic activity of long-acting G-CSF in comparison with standard G-CSF [24]. However, we detected no significant difference in FN between the two groups (6.1% vs. 17.1%; *p* = 0.297). This result indicated that neutropenia can be classified as one of the causes of infection. Additionally, there were many other risk factors for early infection, such as hypoalbuminemia, the complications of diabetes, and the late staging of ISS in our patients with MM [25]. Further analysis reported that the common types of early infection included pneumonia, colitis, and fever of unknown origin. Of note, pneumonia was the most frequent type of infection, accounting for more than 50% of early infections in our study. This finding was consistent with the results of other research, such as that by Lavi et al. [26], who strongly recommended chest computed tomography as a routine examination for patients with MM at high risk of infection.

In the present study, the BLD regimen was chosen as the front induction therapy due to the reported pronounced improvements in overall response rate, progression-free survival, and overall survival, especially among patients with high-risk features [27]. As for clinical efficacy, there were no significant differences between the long-acting and standard G-CSF groups. All of our participants achieved PR or better outcomes following the BLD plus G-CSF regimen. The favorable efficacy was partially ascribed to the chemo-sensitization activity of G-CSF to bortezomib via the blockade of stromal cell-derived factor-1/CXC receptor 4 (SDF-1/CXCR4) between myeloma and stromal cells [28, 29].

5. Conclusions
For patients newly diagnosed with MM, the results of this study revealed that domestic long-acting G-CSF administered on day 6 led to marked decreases in early infection and treatment delay relative to standard G-CSF, while no difference was detected between these two regimens in terms of the incidence of FN. Moreover, all of the early infections in this study occurred during the initial second to fourth cycles of the BLD regimen, and the most common type of early infection was pneumonia. In light of these results, it appears appropriate to administer long-acting G-CSF for the prevention of early infection, particularly during the first four courses of chemotherapy. However, there were some deficiencies in this study. One was its small sample size, and another was the single kind of standard treatment protocol employed herein. Future clinical studies with larger sample sizes are necessary to confirm our results.

Declarations

Funding This work was financially supported by the Science and Technology Project of Health Commission of Jiangxi Province, China Grant no. 20204282.

Conflicts of interest/Competing interests: None.

Availability of data and material: Not applicable.

Code availability: Not applicable.

Authors’ contributions: Xinjing Ding drafted the manuscript and analyzed the data. Jianghua Ding revised the manuscript and produced the figures. Hong Gu and Chuanxiang Zhong provided the raw data and figures as the patients’ primary medical oncologist. All the authors read and approved the final manuscript.

Ethics approval: Ethical approval was obtained from the ethical committee of the affiliated hospital of Jiujiang University.

Consent to participate: All participants or their guardians signed written informed consent before study enrollment.

Consent to publication: All participants or their guardians signed written informed consent including publication of individual’s data.

Acknowledgments

We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

References
1. Kumar V, Ailawadhi M, Dutta Net al (2021) Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. Clin Lymphoma Myeloma Leuk 21(5):e449–e455

2. Blimark C, Holmberg E, Mellqvist UHet al (2015) Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. HAEMATOLOGICA 100(1):107–113

3. T V, V, G. & A ND (2018) Multiple Myeloma Index for Risk of Infection. J Cancer 9(12):2211–2214

4. Rajkumar SV, Kumar S (2020) Multiple myeloma current treatment algorithms. Blood Cancer Journal 10(9):94

5. Dumontet C, Hulin C, Dimopoulos MAet al (2018) A predictive model for risk of early grade >/= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. LEUKEMIA 32(6):1404–1413

6. Aapro MS, Bohlius J, Cameron DAet al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. EUROPEAN JOURNAL OF CANCER 47(1):8–32

7. Vesole DH, Oken MM, Heckler Cet al (2012) Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study. LEUKEMIA 26(12):2517–2520

8. Palumbo A, Blade J, Boccadoro Met al (2012) How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 12(1):5–11

9. Ding X, Huang W, Peng Yet al (2020) Peglgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. ANNALS OF HEMATOLOGY 99(6):1331–1339

10. Knop S, Gerecke C, Liebisch Pet al (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). BLOOD 113(18):4137–4143

11. Leleu X, Terpos E, Sanz RGet al (2016) An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). AMERICAN JOURNAL OF HEMATOLOGY 91(8):806–811

12. Mey UJ, Brugger W, Schwarb Het al (2017) Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 176(5):770–782

13. Cerchione C, Catalano L, Pareto AEet al (2015) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. SUPPORTIVE CARE IN CANCER 23(2):301–302

14. Cerchione C, Catalano L, Peluso let al (2016) Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. SUPPORTIVE CARE IN CANCER 24(12):4835–4837
15. Cerchione C, De Renzo A, Nappi Det al (2019) Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support. SUPPORTIVE CARE IN CANCER 27(5):1587–1588

16. Escriguela-Vidal F, Laporte J, Albasanz-Puig Aet al (2019) Update on the management of febrile neutropenia in hematologic patients. Rev Esp Quimioter 32(Suppl 2):55–58

17. Valkovic T, Gacic V, Ivandic Jet al (2015) Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors. Turk J Haematol 32(3):234–242

18. Kumar S, Paiva B, Anderson KCet al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. LANCET ONCOLOGY 17(8):e328–e346

19. Balmaceda N, Aziz M, Chandrasekar VTet al (2021) Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC CANCER 21(1):730

20. Jung SH, Kang SJ, Jang HRet al (2014) Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. INTERNATIONAL JOURNAL OF HEMATOLOGY 100(5):473–477

21. Drayson MT, Bowcock S, Planche Tet al (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. LANCET ONCOLOGY 20(12):1760–1772

22. Freifeld AG, Bow EJ, Sepkowitz KAAet al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. CLINICAL INFECTIOUS DISEASES 52(4):e56–e93

23. Li G, Zhang QK, Wei Xet al (2021) [Analysis on Related Factors of Pulmonary Infection in Patients with Multiple Myeloma Treated with Bortezomib]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 29(1):152–157

24. Parker SD, King N, Jacobs TF (2021) Pegfilgrastim

25. Xia J, Wang L, Zhou Xet al (2018) Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 46(6), pp 2230–2237

26. Lavi N, Avivi I, Kra-Ozet al (2018) Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. SUPPORTIVE CARE IN CANCER 26(7):2425–2431

27. Cook J, Johnson I, Higgins Aet al (2021) Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. AMERICAN JOURNAL OF HEMATOLOGY 96(3):330–337

28. Petit I, Szyper-Kravitz M, Nagler Aet al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. NATURE IMMUNOLOGY 3(7):687–694

29. Su J, Zhang L, Zhang Wtet al (2014) Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling. PLoS One
